Experience

Davis Polk advised Gilead Sciences, Inc. in connection with an SEC-registered offering of $7.25 billion aggregate principal amount of senior notes, consisting of (i) $500 million aggregate…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Hologic, Inc. of $950 million aggregate principal amount of its…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €6.25 billion aggregate principal amount of notes by Medtronic Global…

 Davis Polk advised ADC Therapeutics SA on its SEC-registered offering of 6,000,000 common shares for total gross proceeds of $204 million. ADC Therapeutics is listed on the New York…

Davis Polk advised Zai Lab Limited in connection with its secondary listing and initial public offering on the Hong Kong Stock Exchange. Zai Lab is the first company listed under both…

Davis Polk advised the representatives of the several underwriters in connection with the $1.3 billion initial public offering of 39,807,691 shares of Class A common stock of GoodRx…

Davis Polk advised the representatives of the initial purchasers in a Rule 144A offering by Omnicell, Inc. of $575 million aggregate principal amount of 0.25% convertible senior notes due…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 9,200,000 shares of common stock of…

Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…

Davis Polk advised the representatives of the several underwriters in connection with the follow-on offering of 4,791,665 shares of common stock of Natera, Inc. for total gross…